By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Bristol-Myers Squibb Company 

345 Park Avenue

New York  New York  10154  U.S.A.
Phone: 212-546-4000 Fax: 212-546-4020


Key Statistics

Ownership: Public

Web Site: Bristol-Myers Squibb
Symbol: BMY



PanVera LLC 

Pharmagene Laboratories Limited 

Johnson & Johnson 

Amersham Biosciences 

Lexicon Genetics Incorporated 

Athersys  Athersys will provide Bristol-Myers Squibb with cell lines expressing validated drug targets produced using the RAGE-Validated Target technology. BMS plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated targets.

Merck & Co.  Diabetes

Affinimark Technologies Inc. 

GlaxoSmithKline (North Carolina) 

Medarex, Inc. 

Gilead (Durham, NC) 

Phyton Biotech, Inc.  - Cancer

Gilead (Seattle, WA) 

Company News
ASCO15 EXCLUSIVE: Late-Breaking Bristol-Myers Squibb (BMY) Data Renew Tumor Drug Hopes 5/29/2015 7:59:56 PM
ASCO15: Bristol-Myers Squibb (BMY) To Hold Investor Teleconference To Discuss ASCO Highlights 5/29/2015 12:27:18 PM
Bristol-Myers Squibb (BMY) Announces The Expiration Of Its Cash Tender Offer 5/27/2015 10:43:55 AM
uniQure (QURE) Announces Closing Of Strategic Collaboration With Bristol-Myers Squibb (BMY) To Develop Gene Therapies For Cardiovascular Disease 5/26/2015 9:41:18 AM
Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion In The European Union For Nivolumab (Opdivo, Nivolumab BMS) For The Treatment Of Advanced Squamous Non-Small Cell Lung Cancer In Previously-Treated Patients 5/22/2015 9:30:50 AM
Bristol-Myers Squibb (BMY) Receives Amended FDA Breakthrough Therapy Designation For Investigational Daclatasvir-Based Hepatitis C Regimen 5/20/2015 11:20:57 AM
AbbVie (ABBV), Bristol-Myers Squibb (BMY) Drug Delays Blood Cancer Progression 5/14/2015 6:55:12 AM
Bristol-Myers Squibb (BMY) Announces The Pricing Terms Of Its Cash Tender Offer For Up To $500 Million Aggregate Principal Amount Of Its Outstanding Debt Securities 5/13/2015 1:23:34 PM
Bristol-Myers Squibb (BMY) To Present Data At 2015 ASCO Annual Meeting That Demonstrate The Promise Of Its Broad Immuno-Oncology Portfolio Across Solid Tumors And Blood Cancers Including Multiple Myeloma 5/13/2015 11:26:45 AM
Bristol-Myers Squibb (BMY) Announces The Early Results Of Its Cash Tender Offer For Up To $400 Million Aggregate Principal Amount Of Its Outstanding Debt Securities; Increases The Maximum Amount Of The Tender Offer 5/12/2015 8:07:24 AM